How much emphasis do you place on anti-AR therapy in a patient with metastatic castration resistant prostate adenocarcinoma with progressive neuroendocrine differentiation?
In a patient with a prior response to ADT and progression on taxane and platinum chemotherapy, would you consider AR directed therapy?
Answer from: Medical Oncologist at Academic Institution
While most prostate cancers are adenocarcinomas, there is a histologic spectrum that includes neuroendocrine and small cell tumors -- with the later typically arising in response to chronic androgen deprivation therapy. Often times we are faced with mixed histologies, which can be challenging to man...
Sign in or Register to read more